Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Anti-angiogenic therapy, primarily targeting VEGF signaling, improves progression-free survival in cancers like colon cancer but shows limited impact on overall survival due to resistance.
• Tumor resistance mechanisms and adaptive responses, particularly those involving hypoxia and metabolic changes, are critical factors limiting the efficacy of anti-VEGF therapies.
• Hypoxia-inducible factors (HIFs) drive significant gene expression, metabolic reprogramming, and phenotypic changes, including increased invasion and metastasis, in response to anti-angiogenic treatment.

Purpose of the Study:

• To explore the mechanisms of resistance to anti-angiogenic therapy.
• To investigate the role of hypoxic and metabolic tumor responses in adaptation to anti-angiogenic therapy.
• To evaluate the potential of combining anti-angiogenic therapy with inhibitors of tumor hypoxic and metabolic adaptation.

Main Methods:

• Review of pre-clinical studies combining anti-angiogenics with inhibitors of tumor hypoxic and metabolic adaptation.
• Analysis of clinical trial data for combination therapies.
• Investigation into personalized therapeutic interventions considering individual patient response and timing.

Main Results:

• Pre-clinical studies combining anti-angiogenics with inhibitors targeting tumor hypoxia and metabolic adaptation have demonstrated significant promise.
• Combination clinical trials have been initiated based on promising pre-clinical data.
• Understanding patient-specific responses and optimal timing is crucial due to the complex effects of anti-angiogenics on tumor vasculature.

Conclusions:

• Combining anti-angiogenic therapy with agents targeting tumor hypoxic and metabolic adaptation represents a promising future therapeutic strategy.
• Developing personalized therapeutic interventions requires a deeper understanding of individual patient responses and the timing of treatment.
• Targeting the hypoxic tumor microenvironment offers potential for synthetic lethality when combined with anti-angiogenic therapy.